# A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

> **NCT05915026** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 93 (actual)

## Conditions studied

- Contrast Enhancement in Magnetic Resonance Imaging
- Children

## Interventions

- **DRUG:** Gadoquatrane (BAY1747846)

## Key facts

- **NCT ID:** NCT05915026
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-16
- **Primary completion:** 2024-09-18
- **Final completion:** 2024-10-16
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05915026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05915026, "A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05915026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*